There Is No Difference—They Are the Same Thing
"Shingles vaccine" and "herpes zoster vaccine" refer to the exact same vaccine, as shingles is simply the common name for herpes zoster. The confusion likely arises because two different vaccines have been used over time: the older live-attenuated vaccine (Zostavax) and the newer recombinant vaccine (Shingrix) 1, 2.
Current Vaccine Recommendation
- Shingrix (recombinant zoster vaccine, RZV) is the only vaccine you should use for adults aged 50 and older 1, 2.
- The older live-attenuated vaccine Zostavax is no longer preferred due to dramatically inferior efficacy—Zostavax efficacy drops to only 14.1% by year 10, compared to Shingrix maintaining >83.3% efficacy for at least 8 years 1, 3, 4.
- Shingrix demonstrates 97.2% efficacy in preventing herpes zoster in adults aged 50+ years, compared to Zostavax's initial efficacy of only 46-70% 1, 3, 5.
Standard Dosing Schedule
- Administer Shingrix as a 2-dose series with the second dose given 2-6 months after the first dose 1.
- The minimum interval between doses is 4 weeks; if given earlier, repeat the dose 1.
- For immunocompromised adults aged ≥18 years, use a shortened schedule with the second dose at 1-2 months 1, 2.
Key Clinical Advantages of Shingrix Over Zostavax
- Shingrix is safe for immunocompromised patients, unlike Zostavax which is absolutely contraindicated in this population due to risk of disseminated VZV infection 1, 2, 3.
- Efficacy remains high across all age groups (>90% even in adults ≥70 years), whereas Zostavax efficacy plummeted with age (70% in ages 50-59 vs. only 18% in those ≥80 years) 1, 5.
- Protection is durable with minimal waning over 8+ years 1, 5.
Important Clinical Scenarios
- Adults who previously received Zostavax should still receive the full 2-dose Shingrix series at least 2 months after the last Zostavax dose 1.
- Vaccinate regardless of prior shingles history—wait at least 2 months after acute symptoms resolve 1.
- Prior shingles does not provide reliable protection; 10-year cumulative recurrence risk is 10.3% 1.
Common Pitfalls to Avoid
- Never use Zostavax in immunocompromised patients—only Shingrix is appropriate 1, 2.
- Do not confuse varicella (chickenpox) vaccine with herpes zoster vaccine—they prevent different manifestations of VZV infection 2.
- Do not delay Shingrix vaccination in patients who previously received Zostavax; the live vaccine provides inadequate long-term protection 1.